A Bayesian response-adaptive trial in tuberculosis: The <i>endTB</i> trial

Abstract

Given the objective of evaluating several new therapeutic regimens in a timely fashion, Bayesian response-adaptive designs are attractive for tuberculosis trials. This approach tends to increase allocation to the effective regimens.